Peptides for Bedlington Terrier skin and coat
The short answer
Bedlington Terriers carry an elevated predisposition to skin and coat. The compounds investigated for it are GHK-Cu. At a typical Bedlington Terrier weight of 8–10 kg (18–22 lb), this breed falls in the small / toy breed dosing class. Critically, this breed carries a genetic trait that changes what is safe: Inherited copper storage disease — GHK-Cu contraindicated by the injectable route
The Bedlington Terrier-specific risk
⚠ Inherited copper storage disease — GHK-Cu contraindicated by the injectable route
Bedlington Terriers carry an autosomal recessive copper storage disorder caused by a COMMD1 gene deletion, which prevents normal biliary copper excretion and leads to progressive hepatic accumulation and cirrhosis. Injectable GHK-Cu introduces additional copper into a system already unable to clear it and should not be used. Topical application produces minimal systemic absorption and is the only route worth considering, with hepatic monitoring.
Relevant to this condition: this affects GHK-Cu, which is among the compounds investigated for skin and coat.
Skin and coat in Bedlington Terriers
Coat quality is often the first visible sign of an underlying problem — endocrine disease, allergy, parasites, or nutritional deficiency — so the first step is always establishing why rather than treating the appearance. Where a specific dermatologic problem is being managed, GHK-Cu is the compound with the most relevant research, largely from human dermatology, and the topical route is both the best studied and the lowest risk since systemic copper exposure is minimal.
Dosing at Bedlington Terrier body weight
Calculated for a 9 kg (20 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 9 kg | Frequency | Evidence |
|---|---|---|---|
| GHK-CuBREED RISK | 0.5-1 mg per day injectable, or topical twice daily | Daily (injectable) / twice daily (topical) | Emerging evidence |
Weigh your dog rather than using a breed average — an individual Bedlington Terrier can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for skin and coat in Bedlington Terriers?+
GHK-Cu are investigated for skin and coat. Note that Bedlington Terriers carry a specific genetic consideration: Inherited copper storage disease — GHK-Cu contraindicated by the injectable route
How much should a Bedlington Terrier be given?+
Bedlington Terriers typically weigh 8–10 kg (18–22 lb), placing them in the small / toy breed class. . Weigh your dog rather than relying on a breed average.
Are Bedlington Terriers more prone to skin and coat?+
Yes. Bedlington Terriers carry an elevated predisposition to skin and coat. Coat quality, hair regrowth, and chronic dermatologic conditions.
References
- 1.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
- 2.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
- 3.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
- 4.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
Other conditions Bedlington Terriers are predisposed to: .
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.